Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia

Launched by MOHAMMED ABD EL MAWGOUD AMER · May 9, 2022

Keywords

ClinConnect Summary

Androgenetic alopecia may affect self-esteem and quality of life in several affected individuals. There are two FDA-approved drugs for pattern baldness: topical minoxidil and finasteride, both of which require at least a 4- to 6-month trial before noticing improvement and must be used indefinitely to maintain a response. As such, medication adherence often can be poor. Furthermore, initiation of the drug may cause an initial shedding phase.

Minoxidil was the first and, so far, the only topical product that has been FDA approved for the treatment of AGA. Minoxidil was originally developed a...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects clinically and dermoscopic diagnosed with AGA.
• • Age ranges from 18 to 45 years old.
• • Males
• • Willingness to provide pictures and follow-up studies.
• Exclusion Criteria:
• • Patients who received any topical or systemic treatment for AGA during the last 6 months,
• • Patients who had other types of alopecia such as alopecia areata, alopecia totalis, telogen effluvium, anagen effluvium, and acquired cicatricial alopecia.
• • Patients with anemia, thyroid disease, and vitamin D deficiency,
• • Any autoimmune disease or chronic debilitating disease (chronic renal failure, congestive heart failure, hepatic patients, cancer patients).